Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication
December 5, 2024 |
We are pleased to share that The Evidence Base have carried out a ‘deep dive’ into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights for real-world impact. The presentation had previously been delivered to a full house at ISPOR Europe 2024 by Priti Jhingran, Smita Kothari, Dominic Jones-Phillips, and Carole Longson, MBE.
In a dynamic healthcare landscape defined by evolving policies, shifting payer expectations, and changing pricing thresholds, stakeholder insights are essential to maintaining the relevance, adaptability, and effectiveness of economic models in addressing the needs of patients and healthcare systems. By integrating perspectives from clinicians, payers, providers, and patients into the development process, economic models are better positioned to withstand rigorous scrutiny in access and reimbursement evaluations, increasing their robustness and applicability in the real-world healthcare environment.
At ISPOR Europe 2024 (November 17–20, 2024, Barcelona, Spain), the presentation, “Planning with Insights: Even the Best Economic Models Need Validation,” delved into this topic, exploring a roadmap for building robust, stakeholder-informed economic models that effectively support reimbursement decisions while addressing the complexities of global markets. Using a case study to illustrate the impact of insights on economic models, the session, which drew a capacity crowd, was led by Priti Jhingran (Genesis Research Group) and included contributions from Dominic Jones-Phillips (Genesis Research Group), Smita Kothari (Merck & Co., Inc.) and Carole Longson, MBE (consultant).
“When you bake in insights in early stages of model development, you really have a higher likelihood of having a relevant model, as well as scientifically robust methodology used to develop the model. And what’s most important is that you get the framework right for the model.”
Also at ISPOR Europe 2024, Genesis Research Group led an issue panel on ‘Precision or Perception: Strategic Drug Pricing Anchored on Evidence’ with Priti Jhingran, PhD, Genesis Research Group, Christopher Blanchette, PhD, MBA, Novo Nordisk, Frank-Ulrich Fricke, PhD, Technische Hochschule Nürnberg, and Adam Weston, MSc, Genesis Research Group.
If you’d like copies of the slides for either presentation, please contact solutions@genesisrg.com.
Read more on ‘Planning with Insights: Even the Best Economic Models Need Validation’
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright's HEOR Theater presentation 'MFN Pricing: More Fun to Navigate – A European Roadmap to Success,' with potentially...
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice...
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice...
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...
Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act
To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to...